TSTamara Sarkisian

Tamara Sarkisian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tamara Sarkisian has a total of 292 co-authors. Here are the top co-authors by number of shared publications:

  • Hasmik Hayrapetyan

    Department of Molecular Genetics, Morava Scientific & Technology Services, Glendale, California

    6 shared publications
  • Gilles Grateau

    Assistance Publique Hôpitaux de Paris and Hôpital Tenon, Paris, France

    5 shared publications
  • Hasmik Hayrapetyan

    Department of Medical Genetics, Yerevan State Medical University, Yerevan, Armenia

    5 shared publications
  • R M Arutiunian

    5 shared publications
  • H Hayrapetyan

    Center of Medical Genetics and Primary Health Care, Yerevan, Armenia

    4 shared publications
  • I. Emerit

    Department of Cytogenetics and Free Radical Research Group, Institut biomédical des Cordeliers, University Paris VI, 15, rue de l’Ecole de Médecine, F-75006 Paris, France Tel., Fax: +33-0143299939

    4 shared publications

Latest Publications

  • Reply to “Correspondence on: EULAR/PRES endorsed recommendations for the management of FMF: 2024 update”

    by Seza Ozen, Ahmet Gül, Cristiana Sieiro Santos, Erdal Sağ, Helen J Lachmann, Jasmin Kuemmerle Deschner, Marco Gattorno, Nuray Aktay-Ayaz, Ömer Karadağ, Shaye Kivity, et al.

  • Top Cited Papers
    Open Access

    EULAR/PReS endorsed recommendations for the management of familial Mediterranean fever (FMF): 2024 update

    by Seza Ozen, Erdal Sağ, Teresa Oton, Ahmet Gül, Cristiana Sieiro Santos, Deniz Bayraktar, Fabian Nikolai Proft, Helen J. Lachmann, Jasmin Kuemmerle Deschner, Marco Gattorno, et al.


  • Diagnostic delays in familial Mediterranean fever: a Juvenile Inflammatory Rheumatism (JIR) cohort study

    by Rim Bourguiba, Samuel Deshayes, Gayane Amaryan, Isabelle Kone-Paut, Alexandre Belot, Tamara Sarkisyan, Rahma Guedri, Manel Mejbri, Isabelle Melki, Ulrich Meinzer, et al.

    Several studies reported that Familial Mediterranean Fever (FMF) diagnosis may be missed or delayed even in countries with a high FMF prevalence. Our aim was to study on a large cohort of European FMF patients the frequency and associated factors of diagnosis delay. Clinical data were extracted from the Juvenile Inflammatory Rheumatism (JIR)-cohort. All FMF patients fulfilled Livneh Criteria and had been sequenced for MEFV exon 10. FMF-diagnostic delay (d-FMF) was defined as the duration between the onset of the symptoms and the diagnosis of more than 10 years. 960 FMF patients were enrolled: delayed diagnosis (d-FMF) was noted in 200 patients (20%). d-FMF patients were significantly older compared to non d-FMF with a median age of 46.4 years old vs. 15.5 (p < 0.0001). Women displayed more d-FMF compared to men (56 vs. 47%, p = 0.03). Clinical presentation during attacks was not statistically significant except for erysipelas-like erythema, which was higher among d-FMF patients (33 vs. 22%, p = 0.0003). The presence of one or two pathogenic MEFV mutation was not different between patients. Compared to other FMF, d-FMF patients displayed significantly more AA amyloidosis (10 vs. 2.6%, p < 0.0001) and received more biotherapy (18 vs. 3.8%, p < 0.0001). Twenty percent of FMF patients had a diagnostic delay >10 years, including more women. The differential diagnosis of abdominal attacks with menstrual pain may be an explanation, and erysipelas-like erythema may not be recognized as FMF by all practitioners.


  • Plasminogen activator inhibitor-1 genotype 4G/5G associates with skin involvement in Armenian familial Mediterranean fever patients

    by Gernot Kriegshäuser, Hasmik Hayrapetyan, Christian Oberkanins, Tamara Sarkisian

    There is little and conflicting data on the role of the plasminogen activator inhibitor-1 (PAI-1, SERPINE1) 4G/5G polymorphism in familial Mediterranean fever (FMF). Therefore this study aimed at evaluating the impact of this polymorphism on the disease course in a cohort of 303 Armenian FMF patients. Genotyping for 12 Mediterranean fever (MEFV) gene mutations and the PAI-1 4G/5G (rs1799762) polymorphism were performed by PCR/reverse-hybridization (StripAssay) and real-time PCR, respectively. PAI-1 genotypes 4G/4G, 4G/5G, and 5G/5G could be identified in 4 (5.88%), 30 (18.63%) and 9 (12.16%) patients with erysipelas-like erythema (ELE), while this was the case for 64 (94.12%), 131 (81.37%), and 65 (87.84%) patients without ELE, respectively (P < 0.033). We have identified a significant relationship between the PAI-1 4G/5G genotype and the occurence of ELE in a relatively large cohort of Armenian FMF patients. Because of conflicting results concerning the impact of this polymorphism on the clinical course of FMF in different populations, further studies are desirable to substantiate the findings reported here.


  • Business Planning for Biobanks

    by Svetlana Gramatiuk, Tanja Macheiner, Tamara Sarkisian, Armen Muradyan, Gariele Hartl

  • Quality Control and Risk Management in Biobanks

    by Gabriele Hartl, Tanja Macheiner, Svetlana Gramatiuk, Mykola Alekseenko, Tamara Sarkisian, Karine Sargsyan

  • Collection and Management of Samples

    by Karine Sargsyan, Svetlana Gramatiuk, Mykola Alekseenko, Tanja Macheiner, Gabriele Hartl, Tamara Sarkisian, Zisis Kozlakidis, Erik Steinfelder, Armen Muradyan, Christine Mitchell, et al.

  • Open Access

    Germline mutational spectrum in Armenian breast cancer patients suspected of hereditary breast and ovarian cancer

    by Mike M. Moradian, Davit T. Babikyan, Sione Markarian, Jonny G. Petrosyan, Nare Avanesian, Tereza Arutunyan, Tamara F. Sarkisian

    Hereditary breast and ovarian cancer (HBOC) can be identified by genetic testing of cancer-causing genes. In this study, we identified a spectrum of genetic variations among 76 individuals of Armenian descent either with a family history of cancer or breast cancer before the age of 40. We screened 76 suspected HBOC patients and family members as well as four healthy controls using a targeted and hereditary comprehensive cancer panel (127 genes). We found 26 pathogenic (path) and 6 likely pathogenic (LPath)variants in 6 genes in 44 patients (58%); these variants were found in BRCA1 (17), BRCA2 (19), CHEK2 (4), PALB2 (2), and NBN (1). A few different variants were found in unrelated individuals; most notably, variant p.Trp1815Ter in the BRCA1 gene occurred in four unrelated patients. We did not find any known significant variants in five patients. Comprehensive cancer panel testing revealed pathogenic variants in cancer genes other than BRCA1 and BRCA2, suggesting that testing only BRCA1 and BRCA2 would have missed 8 out of 44 suspected HBOC patients (18%). These data also confirm that a comprehensive cancer panel testing approach could be an appropriate way to identify most of the variants associated with hereditary breast cancer.


  • Open Access

    The FKBP4 Gene, Encoding a Regulator of the Androgen Receptor Signaling Pathway, Is a Novel Candidate Gene for Androgen Insensitivity Syndrome

    by Erkut Ilaslan, Renata Markosyan, Patrick Sproll, Brian J. Stevenson, Malgorzata Sajek, Marcin P. Sajek, Hasmik Hayrapetyan, Tamara Sarkisian, Ludmila Livshits, Serge Nef, et al.

    Androgen insensitivity syndrome (AIS), manifesting incomplete virilization in 46,XY individuals, is caused mostly by androgen receptor (AR) gene mutations. Therefore, a search for AR mutations is a routine approach in AIS diagnosis. However, some AIS patients lack AR mutations, which complicates the diagnosis. Here, we describe a patient suffering from partial androgen insensitivity syndrome (PAIS) and lacking AR mutations. The whole exome sequencing of the patient and his family members identified a heterozygous FKBP4 gene mutation, c.956T>C (p.Leu319Pro), inherited from the mother. The gene encodes FKBP prolyl isomerase 4, a positive regulator of the AR signaling pathway. This is the first report describing a FKBP4 gene mutation in association with a human disorder of sexual development (DSD). Importantly, the dysfunction of a homologous gene was previously reported in mice, resulting in a phenotype corresponding to PAIS. Moreover, the Leu319Pro amino acid substitution occurred in a highly conserved position of the FKBP4 region, responsible for interaction with other proteins that are crucial for the AR functional heterocomplex formation and therefore the substitution is predicted to cause the disease. We proposed the FKBP4 gene as a candidate AIS gene and suggest screening that gene for the molecular diagnosis of AIS patients lacking AR gene mutations.


  • Serum amyloid A1 genotype associates with adult-onset familial Mediterranean fever in patients homozygous for mutation M694V

    by Gernot Kriegshäuser, Hasmik Hayrapetyan, Stepan Atoyan, Christian Oberkanins, Tamara Sarkisian

    Objectives: FMF shows considerable variability in severity and type of clinical manifestations by geographic region, which are attributed to Mediterranean fever (MEFV) gene allelic heterogeneity, additional genetic modifiers and environmental factors. Considering the severe impact of MEFV mutation M694V on the FMF phenotype, this work aimed at investigating a possible disease modifying role of the serum amyloid A1 (SAA1) genotype in a cohort of 386 Armenian FMF patients homozygous for MEFV mutation M694V. Methods: A cohort of 386 Armenian patients diagnosed with FMF based on the Tel-Hashomer criteria and carrying two MEFV M694V mutant alleles were included in this study. Fifty-two (13.40%) of these patients experienced their first attack at the age of ≥20 years (i.e. adult-onset FMF). MEFV and SAA1 analyses were performed by a commercial reverse-hybridization assay, and resulting genotypes were matched against the patients’ clinicodemographic profiles. Results: Genotypic distribution of SAA1 alleles was significantly different between patients with an age of onset <20 and ≥20 years. SAA1 genotypes α/α, α/β and β/β could be identified in 8 (15.38%), 12 (23.08%) and 32 (61.54%) adult-onset patients while this was the case for 47 (14.07%), 172 (51.50%) and 115 (34.43%) patients with a disease onset <20 years, respectively (P < 0.001). Furthermore, adult-onset disease was associated with a less severe FMF phenotype (P < 0.001). Conclusion: We have identified a significant relationship between the SAA1β/β genotype and the age of disease onset in M694V homozygous FMF patients.